Show summary Hide summary
President Donald Trump just signed a historic executive order directing the FDA to expedite review of psychedelic drugs for mental health treatment. The order, signed April 18, 2026, targets breakthrough therapies including psilocybin, ibogaine, LSD and MDMA. This move promises life-changing treatments for veterans battling PTSD and depression.
🔥 Quick Facts
- $50 Million Funding: Federal government allocates $50 million for state-level ibogaine research programs
- FDA Guidance: FDA must issue new clinical trial protocols for psychedelic drug researchers
- Approval Timeline: FDA drugs can now get approved in weeks instead of a year or longer
- Right to Try Access: Ibogaine pathway opens for desperately ill patients under existing Right to Try law
Trump Signs Historic Psychedelics Reform Order
President Trump signed the groundbreaking order in the Oval Office on Saturday, April 18, alongside federal health officials, HHS Secretary Robert F. Kennedy Jr., FDA Commissioner Marty Makary, and podcaster Joe Rogan. The move aims to revolutionize access to psychedelic therapies for Americans suffering from severe mental illness.
Trump stated the order will “dramatically accelerate access to new medical research and treatments based on psychedelic drugs.” He emphasized that these experimental treatments show “life-changing potential” for those battling depression and trauma, particularly citing the urgent veteran suicide crisis affecting the nation.
Trump executive orders FDA to expedite psychedelics review, cites veterans’ mental health
Victoria Beckham named to TIME100 list, designer from Spice Girls turned fashion icon
What the Executive Order Actually Does
The order implements several transformative steps. The FDA will issue new guidance on conducting clinical trials with psychedelics designated as “breakthrough therapy” drugs, clearing away unnecessary bureaucratic hurdles. The order also establishes data sharing improvements between the FDA and the Department of Veterans Affairs.
Steps include facilitating expedited rescheduling of psychedelics once FDA approved, with three national priority vouchers designated for psychedelic medications. According to Commissioner Makary, this means drugs can gain approval in weeks timeframe instead of the traditional year-plus process currently required by agencies.
Breakthrough Psychedelics and Approval Timeline
| Element | Status or Action |
| Psilocybin | Breakthrough therapy designation, expedited FDA review |
| MDMA (Ecstasy) | Breakthrough therapy status, clinical trials underway |
| Ibogaine | First investigational new drug clearance granted, human trials beginning |
| Approval Timeline | Weeks instead of one year or longer |
The order specifically targets psychedelics with breakthrough therapy status already assigned by the FDA. These compounds have shown substantial improvement over existing treatments in preliminary clinical evidence. Psilocybin and MDMA both hold this designation, making them eligible for expedited pathways under Trump’s directive.
Veterans Mental Health Crisis Drives Action
“In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans.”
— President Donald Trump, at the White House executive order signing
Trump emphasized the veteran suicide epidemic as a core motivation. According to the order, HHS Secretary Kennedy called the initiative essential for confronting “one of the most urgent public health challenges facing our nation, the mental health crisis.”
The federal government is committing $50 million to support state-level research on ibogaine specifically. Additionally, the order opens a new pathway for desperately ill patients to access ibogaine under Trump’s Right to Try law from his first term, bypassing lengthy approval timelines for end-stage conditions.
Why Is This Moment Historic for Psychedelics?
For decades, Schedule I drug restrictions blocked serious research into compounds like psilocybin, MDMA, and ibogaine. Scientific evidence increasingly shows these substances help PTSD, depression, traumatic brain injuries, and addiction when administered in controlled clinical settings with professional supervision.
Trump’s order removes legal impediments allowing American researchers and clinicians to properly study these medicines and establish safe therapeutic protocols. FDA Commissioner Makary announced the first ibogaine investigational clearance, paving the way for the first-ever human trials in the United States. Will this historic moment finally unlock psychedelic therapy for millions suffering Americans?
Sources
- Fox News – Trump signs executive order directing FDA to review psychedelics designated as breakthrough therapy drugs
- Marijuana Moment – Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental Health Conditions
- Reuters – Trump set to ease restrictions on psychedelic drug used to treat PTSD
